Route 92 Medical, a San Mateo, CA-based company developing solutions for neurovascular interventional procedures, received $50M in Series F extension equity funding.
The round was led by Novo Holdings. Other participants in the round included U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group. In connection with the investment, Noel Jee, Partner, Growth Investments, Novo Holdings US, joins the Route 92 Board of Directors.
The company intends to use the funds to accelerate the global commercialization of its neurovascular intervention portfolio, and to pursue regulatory authorizations in new geographies.
Led by CEO Tony Chou, Route 92 Medical aims to improve outcomes for patients undergoing neurovascular intervention through engineering and innovative product design. The company collaborates with neurovascular clinicians to solve challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success.
The procedures include its FreeClimb and HiPoint Catheter Systems and Monopoint® Operating Platform, empowered by its Tenzing® Delivery Catheter. Route 92’s technology is designed to simplify and streamline stroke treatment, creating single-operator control over all elements, with the goal of reducing procedure time and cost while improving patient outcomes.
FinSMEs
24/09/2024